Tamoxifen has also been studied as a preventive therapeutic agent in cases considered at high risk of developing BC (such as those with BRCA1/2 mutations, a family history of the disease, or early menarche) or in patients with a history of BC to minimize the risk of recurrence [35,36]. This evidence concerns the gene BRCA1 and breast cancer.